Trials / Active Not Recruiting
Active Not RecruitingNCT05020652
A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
A Randomized, Double Blind, Double Dummy, Parallel Controlled, Multicenter Phase II Clinical Trial of TQ05105 Tablets Versus Hydroxyurea Tablets in the Treatment of Moderate and High Risk Myelofibrosis
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 107 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Q05105 tablet is a Janus kinase 2 (JAK2) inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ05105 tablets | TQ05105 tablet is a JAK2 inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis. |
| DRUG | Hydroxycarbamide tablets | Hydroxycarbamide tablet is a nucleoside diphosphate reductase inhibitor. |
Timeline
- Start date
- 2021-11-11
- Primary completion
- 2023-10-15
- Completion
- 2026-02-01
- First posted
- 2021-08-25
- Last updated
- 2025-12-17
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05020652. Inclusion in this directory is not an endorsement.